PRIMERY RESULTS ON PLASMA TESTING FROM BLOOD DONORS TO THE PRESENCE OF ANTI-SARS-CoV-2 FOR THE TREATMENT OF COVID-19 PATIENTS
The data obtained show that practically 87.4% of plasma donors responded to COVID-19 infection by anti-SARS-COV-2 IgG expression with a predominance in the age group 26-35 years. Most donors made mild and moderate clinical forms, which can be explained by the presentation of potentially healthy plasma donors without chronic disease concomitant with COVID-19. No link was identified between the degree of moderate or mild clinical manifestation of the disease and the presence or absence of anti-SARS-CoV-2. It is important to note that all serious clinical forms of COVID-19 infection were accompanied by the formation of anti-SARS-CoV-2 IgG. The urban living environment predominates (75%) in convalescent plasma donors, which indicates that they are better informed by Public Medical Institutions, have access to various Mass-Media sources and public transport to travel to donation points. The study shows that blood donors, males aged 18-60 years with a history of COVID-19 disease, etiologically confirmed, subsequently cured; with a negative result (PCR) at least 14 days after clinical recovery can serve the source of fresh plasma used for the treatment of COVID-19 patients, especially with severe (severe) forms of clinical manifestation of the disease.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.